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ABSTRACT. Variation in the gene encoding cyclooxygenase-1 
(COX-1) is involved in the process of aspirin resistance. This study 
investigated the genetic variations in the COX-1 gene. The 4 coding 
regions of the human COX-1 gene in 90 pediatric patients (median 
age of 6.5 months, 55% males) with cardiovascular anomalies were 
screened using DNA sequencing. Twenty coding-region variants 
causing amino acid substitutions as well as 2 new non-synonymous 
polymorphisms were identified. All variants were compared with an 
independent Caucasian population (N = 24 unrelated individuals). Most 
of the discovered polymorphisms were rare, although some variants 
resulted in amino acid changes occurring at a frequency >5% (W8R, 
P17L, Q41Q, Q240Q, D189E, and P188P). In addition, 2 new non-
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synonymous polymorphisms (F200L and D189E) were identified. 
These findings demonstrated novel genetic variants of the human COX-
1 gene. Future studies characterizing the functional impact of these 
variants are warranted.
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INTRODUCTION
For primary and secondary prophylaxis, pediatric patients with cardiovascular anoma-
lies are administered aspirin to prevent arterial vascular events (Monagle et al., 2008). In 
children receiving aspirin for diverse indications, incidence of laboratory and clinical aspirin 
resistance following pediatric cardiac surgery was estimated at 2.3% (Yee et al., 2008) and 
10% (Cholette et al., 2010), respectively. Aspirin responsiveness can be influenced by poly-
morphisms in the gene encoding the cyclooxygenase-1 (COX-1) enzyme, causing amino acid 
substitutions that could change the specific activity of COX-1 (Halushka et al., 2003).
The COX-1 gene has been localized to chromosome 9q32-q33.3 and has been cloned 
(Yokoyama and Tanabe, 1989). The gene consists of 11 exons (Funk et al., 1991). Polymor-
phisms in both coding and non-coding regions of the human COX-1 gene have been identified 
(Ulrich et al., 2002), and the COX-1 gene has been re-sequenced as part of the Seattle single-
nucleotide polymorphism (SNP) Variation Discovery Resource (http://pga.mbt.washington.
edu/). In particular, non-synonymous variants encoding amino acid substitutions in the COX-1 
protein have been identified (Scott et al., 2002).
We screened the 4 coding regions of the human COX-1 gene in pediatric patients with 
cardiac anomalies for SNPs, using DNA sequencing. Our primary objective was to identify or 
confirm the existence of SNPs in the COX-1 gene. Subsequently, we determined the allele fre-
quencies of the observed polymorphisms and discovered 2 new non-synonymous polymorphisms.
MATERIAL AND METHODS
Patient selection
In the presented study, we enrolled 90 pediatric patients (50 males and 40 females), 
with cardiovascular anomalies, who were candidates for operative surgery. Twenty-four 
healthy unrelated adults were control subjects. All 114 subjects were Caucasians and from the 
Aegean region of Turkey.
We sequenced 4 of the 11 exons of the COX-1 gene in 90 patients and identified 2 
novel non-synonymous polymorphisms.
DNA extraction and PCR amplification
Genomic DNA was extracted from peripheral blood by using a DNA extraction kit 
(Invitrogen, Carlsbad, CA, USA) following a standard protocol (Miller et al., 1988). To iden-
tify polymorphisms, the coding exons of COX-1 were amplified individually. The primer se-
quences, MgCl2 concentrations, and annealing temperatures for each amplicon are listed in 
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Table 1. Each reaction was amplified with a 25-μL mixture containing 2.5 μL 10X PCR buffer 
with variable MgCl2 concentrations [Applied Biosystems (ABI), Foster City, CA, USA], 2.5 
mM dNTPs, 10 pM of each primer, 0.7 U Taq DNA polymerase (Roche, Mannheim, Ger-
many), and 100 ng genomic DNA. Thermal cycling was performed using a thermal cycler 
(Applied Biosystems 9700) as follows: initial denaturation for 12 min at 95°C; 35 cycles at 
94°C for 30 s, 62°C (exons 2 and 3) or 60°C (exons 6 and 7) for 30 s, 72°C for 30 s; and a final 
extension for 10 min at 72°C.
Exons Primers MgCl2 (mM) Annealing temperature (°C) Amplicon length (bp)
2 Cox1-2112F: 5'-ATGAGCCGTGAGTGCGACCC-3' 1.2 66 351
 Cox1-2462R: 5'-GCTTCAGGGAGCCCCCATC-3'
3 Cox1-8816F: 5'-GAGCTGCGACTTAAGTCCAT-3' 1.5 62 308
 Cox1-9123R: 5'-GGAAGTTAGGGTCTAGGAGA-3'
6 and 7 Cox1-12346F: 5'-GCAGCAAGATCCAGATAGGA-3' 1.0 62 527
 Cox1-12872R: 5'-CTCTCAGGACATGACCCAGA-3'
Table 1. Primers and PCR conditions for COX-1 sequencing.
DNA sequencing
All the amplified products were sequenced bidirectionally using BigDye Terminator 
Mix version 3.1 (Applied Biosystems), according to manufacturer instructions, and were ana-
lyzed on an ABI-3100 Genetic Analyzer (ABI). Nucleotide sequences were compared with the 
published COX-1 gene cDNA sequence in the PARSESNP database (Greene E and Taylor N; 
http://www.proweb.org/parsesnp).
The study was approved by the Ege University Institutional Review Board and con-
ducted according to the ethical principles in the Declaration of Helsinki and Good Clinical 
Practice guidelines. A written informed consent was obtained from parents and each individual.
Statistical analyses were performed with the SPSS statistical package (version 17.0, 
SPSS, Chicago, IL, USA). All numerical data are expressed as median (interquartile range) 
values or proportions. Categorical variables are presented as number of cases (percentage) 
and are compared using the chi-square test. Two-sided P values of less than 0.05 were re-
garded as significant.
RESULTS
The median age was 6.5 months, with an interquartile range of 1 day to 16 years. Of 
these, 8 (8.8%) patients had vascular anomalies such as patent ductus arteriosus (2.2%), aber-
rant subclavian artery (2.2%), and aortic coarctation (4.4%). Eighty-two (91.2%) patients had 
diverse cardiac anomalies (Table 2). The median age was 31 years (18-43) in the control group.
Sequencing of exons 2, 3, 6, and 7 of the COX-1 gene from the 90 pediatric patients of 
known ethnicity identified 20 SNPs. Of these, 7 SNPs were located in exon 2, 8 were located 
in exon 3, and 5 were located in exons 6 and 7. The most frequent SNP was W8R in both 
groups (95.6 and 87.5%, respectively; P = 0.14).
In all subjects, the total number of amino acid substitutions was 143 (73%), and the 
total number of SNPs was 54 (27%); in the study group, the frequencies were 72 and 28%, 
respectively. The most frequent amino acid substitutions were tryptophan to arginine (W8R) 
(93.9%) and proline to proline (P188P) (28.1%) (Table 3).
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Cardiac and vascular anomalies N = 90 (%)
Single ventricule 14 (15.6)
ASD 13 (14.5)
TGV 11 (12.3)
Tetralogy of Fallot 11 (12.3)
VSD 7 (7.7)
Truncus arteriosus 4 (4.5)
Aortic coarctation 4 (4.5)
Subaortic discrete membrane 3 (3.3)
VSD + ASD 2 (2.2)
Aberrant subclavian artery 2 (2.2)
ASD + PAPVR 2 (2.2)
Pulmonary stenosis 2 (2.2)
A-V canal defect 2 (2.2)
VSD + PDA + PFO 2 (2.2)
PDA 2 (2.2)
TAPVR 2 (2.2)
ASD + VSD + TGV 2 (2.2)
Aortic valve stenosis 1 (1.1)
IHSS + mitral valve insufficiency 1 (1.1)
Hipoplastic left  heart 1 (1.1)
VSD + pulmonary atresia 1 (1.1)
Cor triatriatum sinistrum 1 (1.1)
ASD = atrial septal defect; TGV = transposition of the great vessels; VSD = ventricular septal defect; PAPVR = partial 
anomalous pulmonary venous return; A-V = atrio-ventricular; PFO = patent foramen ovale; PDA = patent ductus 
arteriosus; TAPVR = total anomalous pulmonary venous return; IHSS = idiopathic hypertrophic subaortic stenosis.
Table 2. Operated patients with congenital cardiovascular anomalies.
Exons AA substitution Codon NC AA substitution N = 114 %
2 Tryptophan/arginine TGG/CGG T-C W8R 107 93.9
 Proline/leucine CCG/CTG C-T P17L 6 5.3
 Leucine/proline CTG/CCG T-C L13P 2 1.8
 Leucine/leucine CTC/CTG C-G L23L 1 0.9
 Proline/arginine CCG/CGG C-G P18R 1 0.9
 Leucine/tyrosine CTG/GTG C-G L15Y 2 1.8
 Glutamine/glutamine CAG/CAD G-A Q41Q 7 6.1
3 Proline/proline CCA/CCC A-C P39P 2 1.8
 Arginine/arginine CGC/CGA C-A R53R 1 0.9
 Arginine/serine CGC/AGC C-A G44G 1 0.9
 Cysteine/tryptophan TGC/TGG C-G C58W 2 1.8
 Isoleucine/methionine ATC/ATG C-G I45M 1 0.9
 Arginine/histidine CGC/CAC G-A R53H 1 0.9
 Glycine/glycine GGC/GGT C-T G62G 1 0.9
 Glutamine/glutamine CAG/CAA C-A Q240Q 6 5.3
6 and 7 Arginine/leucine CGT/CTT G-T R239L 2 1.8
 Phenylalanine/leucine TTT/TTG T-G F200L 1 0.9
 Aspartic acid/glutamic acid GAC/GAG C-G D189E 20 17.5
 Lysine/threonine AAG/ACG A-C K185T 1 0.9
 Proline/proline CCT/CCC C-C P188P 32 28.1
AA = amino acids; NC = nucleotide change.
Table 3. Distribution of amino acid substitutions and polymorphisms in all subjects.
All variants were compared with an independent Caucasian population (N = 24 un-
related individuals) (Table 4). Two new SNPs were detected, F200L and D189E, encoded in 
exons 6 and 7, respectively. F200L was observed in 1 patient (1.1%) and only in the study 
group (P = 0.60). The frequency of the D189E SNP was 18.9 and 12.5% in the study and con-
trol groups, respectively (P = 0.46).
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Most of the discovered polymorphisms were rare, although some variants resulting in 
amino acid substitutions occurred at a frequency >5%: W8R, P17L, Q41Q, Q240Q, D189E, 
P188P. The polymorphisms found only in the study group corresponded to P17L, L13P, L23L, 
P18R, P39P, R53R, G44G, C58W, I45M, R53S, G62G, Q240Q, R239L, F200L, and K185T. 
In control subjects, W8R, L15Y, Q41Q, D189E, and P188P polymorphisms were observed. 
Only the P188P amino acid substitution was statistically more frequent in the study group than 
in the control group (34.4 vs 4.2%, respectively, P = 0.002).
DISCUSSION
The present study reports the screening of the coding region of the COX-1 gene, 
identification of polymorphisms, their allele frequencies in congenital anomalous patients and 
healthy individuals. We here report on 2 new non-synonymous polymorphisms resulting in 
amino acid substitutions. To our knowledge, this is the first report of allele frequencies on 
COX-1 polymorphisms in pediatric patients with cardiovascular anomalies.
COX-1 is the primary target of aspirin. Genetic variants that affect enzyme function, 
or the protein’s interaction with aspirin, could alter an individual’s drug response. Polymor-
phisms may increase the risk of cardiovascular disease or aspirin resistance (Halushka et al., 
2003). It is unclear whether common variants affect the structure and function of the mature 
enzyme. Thus, it is believed that the differences seen in the function of COX-1 most likely 
result from genetic variation in the regulatory or signal peptide region of the gene or from 
variation in platelet development and aging. Effects of such variation would hypothetically af-
fect either the amount of COX-1 protein or the location of COX-1 protein in the cell (Halushka 
et al., 2003; Lee et al., 2007). COX-1 structure-function studies suggest that several amino 
acid substitutions with modest influence on arachidonic acid binding to the COX-1 active site 
can alter the catalytic efficiency and metabolite profile of COX-1-mediated arachidonic acid 
Exons Codon  Amino acid substitution                                          Variant allele frequency
    Study group [N = 90 (%)] Controls [N = 24 (%)] P
2 TGG/CGG HOM W8R (Trp8Arg) 86 (95.6) 21 (87.5) 0.14
 CCG/CTG HET P17L (Pro17Leu) 6 (6.7) 0 0.19
 CTG/CCG HET L13P (Leu13Pro) 2 (2.2) 0 0.46
 CTC/CTG HET L23L (Leu23Leu) 1 (1.1) 0 0.60
 CCG/CGG HET P18R (Pro18Arg) 1 (1.1) 0 0.60
 CTG/GTG HET L15Y (Leu15Tyr) 1 (1.1) 1 (4.2) 0.31
3 CAG/CAA HET Q41Q (Gln41Gln) 5 (5.6) 2 (8.4) 0.61
 CCA/CCC HET P39P (Pro39Pro) 2 (2.2) 0 0.46
 CGC/CGA HET R53R (Arg53Arg) 1 (1.1) 0 0.60
 GGC/GGG HET G44G (Gly44Gly) 1 (1.1) 0 0.60
 TGC/TGG HET C58W (Cys58Trp) 2 (2.2) 0 0.46
 ATC/ATG HET I45M (Ile45Met) 1 (1.1) 0 0.60
 CGC/CAC HET R53H (Arg53His) 1 (1.1) 0 0.60
 GGC/GGT HET G62G (Gly62Gly) 1 (1.1) 0 0.60
6 and 7 CAG/CAA HOM Q240Q (Gln240Gln) 6 (6.7) 0 0.19
 CGT/CTT HOM R239L (Arg239Leu) 2 (2.2) 0 0.46
 TTT/TTG HET F200L (Phe200Leu) 1 (1.1) 0 0.60
 GAC/GAG HET D189E (Asp189Glu) 17 (18.9)  3 (12.5) 0.46
 AAG/ACG HET K185T (Lys185Thr) 1 (1.1) 0 0.60
 CCT/CCC HET P188P (Pro188Pro) 31 (34.4) 1 (4.2)   0.002
HOM = homozygote; HET = heterozygote.
Table 4. Comparison of polymorphisms.
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metabolism (Thuresson et al., 2001). Perhaps these variants could reduce overall metabolic 
efficiency by altering the interaction between arachidonic acid and the active site. Functional 
studies aid in the interpretation of genetic epidemiological studies evaluating associations 
between COX-1 gene polymorphisms and the risk of diseases that involve altered COX-1-de-
rived prostaglandin synthesis, such as cardiovascular and cerebrovascular disease (Lee et al., 
2008; Lordkipanidzé et al., 2011).
Few non-synonymous coding polymorphisms in the COX-1 gene were discovered, 
and most of these were rare (<5%), based on preliminary allele frequency determinations. 
We were not able to confirm the 2 new non-synonymous polymorphisms reported in the 
PARSESNP database (F200L and D189E).
In summary, we reported 2 new polymorphisms in the COX-1 gene and showed the 
allele frequencies of the new and previously described variants for pediatric patients with 
cardiovascular anomalies. Because the COX-1 enzyme is important in the pharmacology of 
aspirin, genetic polymorphisms that alter enzyme function are of interest. Further studies of 
the functional impact of the 2 new polymorphisms on aspirin metabolism are needed.
While the finding of novel polymorphisms in the COX-1 gene is potentially inter-
esting, there are certain limitations. This is a partial screening of the COX-1 gene-coding 
regions. Although the patient population was given aspirin to prevent arterial vascular events, 
the functional impact of polymorphisms with respect to the aspirin-resistance in patients with 
polymorphisms was not investigated.
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